Skip to main content

Research Repository

Advanced Search

All Outputs (8)

Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells (2023)
Journal Article
Morfitt, M. A., Greenman, J., Maraveyas, A., Harris, A. L., & Nikitenko, L. L. (2023). Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells. Cancer Research, 83(16_Supplement), A020-A020. https://doi.org/10.1158/1538-7445.kidney23-a020

Introduction. Clear cell renal cell carcinoma (ccRCC) is a highly vascularized and clinically aggressive kidney cancer, with high rates of metastasis and recurrence after cytoreductive nephrectomy. ccRCC can be treated with anti-angiogenic drugs, how... Read More about Abstract A020: Calcitonin receptor-like receptor is expressed in blood vessels in clear cell renal cell carcinoma and upregulated in endothelial cells co-cultured with tumor cells.

Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment (2023)
Journal Article
Morfitt, M. A., Greenman, J., Maraveyas, A., & Nikitenko, L. L. (2023). Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment. Cancer Research, 83(16_Supplement), B001-B001. https://doi.org/10.1158/1538-7445.kidney23-b001

Introduction. Clear cell renal cell carcinoma (ccRCC) is a highly vascularized and clinically aggressive cancer. In the UK, there are around 9000 diagnoses and 3000 deaths annually. Targeted therapies that inhibit angiogenic regulators, such as bevac... Read More about Abstract B001: Calcitonin receptor-like receptor agonists induce p44/42 MAPK phosphorylation in VEGF-A-stimulated human blood endothelial cells after bevacizumab treatment.

Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients (2022)
Journal Article
Ettelaie, C., Benelhaj, N., Featherby, S., Haque, F., Johnson, M., Cooke, J., & Maraveyas, A. (2022). Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients. Journal of Biotechnology and Biomedicine, 5(2), 78-93. https://doi.org/10.26502/jbb.2642-280050

Predicting which cancer patients are at risk of thrombosis remains a key challenge to effective thromboprophylaxis. This study was based on the hypothesis that the rapid release of TF-containing MV occurs in cancer cells that possess high levels of T... Read More about Tumour-Associated Tissue Factor (TF)-mRNA Is A Precursor for Rapid TF-Microvesicle Release and A Potential Predictive Marker for the Risk of Pulmonary Embolism (PE) in Gastrointestinal Cancer Patients.

Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis (2018)
Journal Article
Benelhaj, N. B., Hutchinson, A., Maraveyas, A. M., Seymour, J. D., Ilyas, M. W., & Johnson, M. J. (2018). Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis. Palliative medicine, 32(5), 1010-1020. https://doi.org/10.1177/0269216318757133

Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience. Aims To identify and sy... Read More about Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis.

Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography (2017)
Journal Article
Adesanya, M. A., Maraveyas, A., & Madden, L. (2017). Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography. Blood Coagulation and Fibrinolysis, 28(8), 602-611. https://doi.org/10.1097/mbc.0000000000000644

© 2017 Wolters Kluwer Health, Inc. All rights reserved. Calibrated automated thrombography (CAT) is emerging as a reliable tool for real-Time estimation of thrombin generation potential. There is a clinical need for knowledge about the pathways under... Read More about Differing mechanisms of thrombin generation in live haematological and solid cancer cells determined by calibrated automated thrombography.

Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro (2017)
Journal Article
Adesanya, M. A., Maraveyas, A., & Madden, L. A. (2017). Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro. Blood Coagulation and Fibrinolysis, 28(5), 365-372. https://doi.org/10.1097/MBC.0000000000000607

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. Microvesicles associated with tissue factor (TF) may play a role in cancer-related venous thromboembolism; however, not much is known about their interaction with the tumour stroma, es... Read More about Cancer microvesicles induce tissue factor-related procoagulant activity in endothelial cells in vitro.

Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy (2010)
Journal Article
Murray, A., Little, S. J., Stanley, P., Cawkwell, L., & Maraveyas, A. (2010). Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy. Oncology Reports, 24(4), 1049-1058. https://doi.org/10.3892/or-00000954

Angiogenesis inhibitors may enhance the effects of low dose (metronomic) chemotherapy. However, there is a wide range of novel angiogenesis inhibitors which must be tested in combinations with oral chemotherapy agents to assess the anti-endothelial a... Read More about Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.